Filana Therapeutics Reports Preclinical Simufilam Findings in TSC2-Deficient Cells

The research reports a 37% reduction in elevated ATF4, consistent with attenuation of the associated cellular stress response, and examines simufilam’s effects on cellular stress responses and mitochondrial function. Patient screening for a planned Phase 2a study is expected to begin.